{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T07:53:50Z","timestamp":1764402830548,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Marrow Donor Program"},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA16520","K23-CA178202","U01-HL069286"],"award-info":[{"award-number":["P30-CA16520","K23-CA178202","U01-HL069286"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017006","name":"Abramson Cancer Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017006","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bbmt.2018.01.037","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T07:31:13Z","timestamp":1517556673000},"page":"1203-1208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors"],"prefix":"10.1016","volume":"24","author":[{"given":"Lisa M.","family":"Crisalli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne T.","family":"Hinkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Walling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Sell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9546","authenticated-orcid":false,"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.01.037_bib0010","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0020","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bbmt.2013.03.016","article-title":"Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia","volume":"19","author":"Chen","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0035","doi-asserted-by":"crossref","first-page":"9387","DOI":"10.1200\/JCO.2005.02.0057","article-title":"Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia","volume":"23","author":"Tauro","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0040","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0045","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0050","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0055","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1200\/JCO.2014.60.1203","article-title":"High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning","volume":"33","author":"Reshef","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0060","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2004-04-1473","article-title":"Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose","volume":"105","author":"Cao","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0065","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbmt.2009.10.004","article-title":"The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes","volume":"16","author":"Collins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3324\/haematol.2015.134841","article-title":"Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation","volume":"101","author":"Martin","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0075","first-page":"4598","article-title":"Doses of total nucleated cells and activated T-cells transplanted influence survival and graft versus host disease among AML and MDS recipients of reduced-intensity mobilized peripheral blood allografts","volume":"128","author":"Richardson","year":"2016","journal-title":"Am Soc of Hematol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0080","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/jca.21292","article-title":"Determining factors predictive of CD34+ cell collection efficiency in an effort to avoid extended and repeated apheresis sessions","volume":"28","author":"Verlinden","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.transci.2011.01.005","article-title":"Large volume leukapheresis: efficacy and safety of processing patient's total blood volume six times","volume":"44","author":"Bojanic","year":"2011","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0090","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jca.1020","article-title":"Prospective, randomized, sequential, crossover trial of large-volume vs. normal-volume leukapheresis procedures: effects on subpopulations of CD34(+) cells","volume":"16","author":"Humpe","year":"2001","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002770100289","article-title":"Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation","volume":"80","author":"Engelhardt","year":"2001","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0100","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0105","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0115","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.leu.2403718","article-title":"High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation","volume":"19","author":"Baron","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0120","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.2006.05.5855","volume":"24","author":"Gorin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0125","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jca.20259","article-title":"Use of various offset settings in the Fenwal Amicus during hematopoietic progenitor cell collection to increase lymphocyte yield and reduce cross-cellular contamination","volume":"25","author":"Burgstaler","year":"2010","journal-title":"J Clin Apher"},{"key":"10.1016\/j.bbmt.2018.01.037_bib0135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/jca.20292","article-title":"Comparison of hematopoietic progenitor cell collections using the COBE Spectra version 7 and Amicus version 3.1 for patients with AL amyloidosis","volume":"26","author":"Burgstaler","year":"2011","journal-title":"J Clin Apher"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118300545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:17Z","timestamp":1761058877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118300545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1083879118300545"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.037","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}